p53 Autoantibodies in Malignant Mesothelioma
Author Information
Author(s): Creaney J, McLaren B M, Stevenson S, Musk A W, Klerk N de, Robinson B W S, Lake R A
Primary Institution: Western Australian Institute for Medical Research and University Department of Medicine, University of Western Australia
Hypothesis
The study aimed to determine the prevalence of anti-p53 antibodies in patients with malignant mesothelioma and their potential as diagnostic or prognostic markers.
Conclusion
Anti-p53 antibodies are found at low frequency in malignant mesothelioma patients and do not serve as useful prognostic or diagnostic indicators.
Supporting Evidence
- 7% of patients had high titres of anti-p53 antibodies.
- There was no correlation between antibody titre and survival.
- 8% of sera from patients exposed to asbestos but prior to diagnosis contained antibodies.
Takeaway
The study looked at blood samples from people with a type of cancer called malignant mesothelioma and found that a specific antibody was not very common and didn't help predict how the disease would progress.
Methodology
The study analyzed blood samples from patients to check for the presence of anti-p53 antibodies and their levels over time.
Limitations
The study had a small sample size and did not find a correlation between antibody levels and patient survival.
Participant Demographics
Patients were from Western Australia, with a history of asbestos exposure.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website